Researcher
Dahham Alsoud
- Disciplines:Gastro-enterology
Affiliations
- Translational Research in GastroIntestinal Disorders (Division)
Member
From15 Sep 2019 → Today
Projects
1 - 1 of 1
- “Predicting response to therapy in inflammatory bowel diseases ”From23 Sep 2019 → 23 Sep 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 10 of 15
- The Serum-Based Endoscopic Healing Index Can Monitor Therapeutic Response in Crohn's Disease(2023)
Authors: Dahham Alsoud, Bram Verstockt
Pages: 1703 - 1704 - Comparative Effectiveness Research to Position Therapies in Ulcerative Colitis: How Fair Are the Comparisons?(2023)
Authors: Dahham Alsoud, Bram Verstockt, Séverine Vermeire
Pages: 1372 - 1373 - Evaluation of serum cytokines and acute phase proteins as possible pharmacodynamic biomarkers to monitor endoscopic remission during ustekinumab therapy in patients with Crohn's disease(2023)
Authors: Nathalie Van den Berghe, Dahham Alsoud, Bram Verstockt, Séverine Vermeire, Paul Declerck, Debby Thomas
- Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative Colitis(2022)
Authors: Dahham Alsoud, Gert De Hertogh, João Guedelha Sabino, Marc Ferrante, Debby Thomas, Séverine Vermeire, Bram Verstockt
Pages: 1562 - 1570 - Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn's disease: real-life cohort from a tertiary referral center(2022)
Authors: Dahham Alsoud, Bram Verstockt, João Guedelha Sabino, Marc Ferrante, Séverine Vermeire
Pages: 1015 - 1020 - Tailoring Multi-omics to Inflammatory Bowel Diseases: All for One and One for All(2022)
Authors: Padhmanand Sudhakar, Dahham Alsoud, Judith Wellens, Sare Verstockt, Kaline Arnauts, Bram Verstockt, Séverine Vermeire
Pages: 1306 - 1320 - Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD(2022)
Authors: Bram Verstockt, Dahham Alsoud, João Guedelha Sabino, Marc Ferrante, Séverine Vermeire
Pages: 1135 - 1142 - Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis(2022)
Authors: Bram Verstockt, Dahham Alsoud, João Guedelha Sabino, Gert De Hertogh, Séverine Vermeire, Marc Ferrante
Pages: 282 - 291 - USTEKINUMAB EFFECTIVENESS, DRUG PERSISTENCE AND SERUM EXPOSURE IN CROHN'S DISEASE ARE AFFECTED BY ITS POSITIONING(2022)
Authors: Dahham Alsoud, João Guedelha Sabino, Marc Ferrante, Séverine Vermeire, Bram Verstockt
Pages: S819 - S819 - Letter: immunogenicity is not the root cause for loss of response to anti-TNF agents in patients with IBD in TDM era(2022)
Authors: Dahham Alsoud, Bram Verstockt, Séverine Vermeire
Pages: 885 - 886